Since we observed a low percentage of carcinomas with NIS staining in the basolateral membrane, we hypothesized that our IHC approach was not being sensitive enough to detect small amounts of NIS. To clarify this issue, we used two strategies: a TSA signal amplification method and the use of another NIS antibody characterized by a different specificity compared to the commercial antibody (36).